Aptar Digital Health Partners with the University of Geneva to Advance Migraine Research
Posted: 27 November 2024 Aptar Digital Health, a global leader in digital health solutions, connected devices, data and study services, today announced a collaboration with the Quality of Life (QoL) technologies lab, University of Geneva, Switzerland, to advance…
Almac’s Singapore facility secures GMP Certification
Posted: 27 November 2024 Almac Clinical Services’ facility in Singapore has received Good Manufacturing Practice certification from the Health Sciences Authority, for cell, tissue and gene therapy products. This certification demonstrates our commitment to upholding the highest standards…
CSIRO solar venture nets record seed funding to accelerate clean energy transition
Posted: 27 November 2024 FPR Energy, a new venture from CSIRO, Australia’s national science agency, has secured $15 million in seed funding to commercialise next generation solar thermal technology that will help reduce industrial emissions, which account for…
Funds to better understand Friedreich ataxia drug
Posted: 27 November 2024 Associate Professor Shiang (Max) Lim, of SVI’s O’Brien Department, has been awarded funding from the Friedreich’s Ataxia Research Alliance (FARA) to better understand the effect of omaveloxolone – a recently FDA-approved drug – on…
St Vincent’s Allied Health Excellence Awards highlight patient care, innovation and leadership
Posted: 27 November 2024 St Vincent’s Hospital Melbourne has honoured its 2024 Allied Health Excellence Awards winners, recognising the pivotal role allied health professionals play in delivering high-quality, multidisciplinary care. With over 60 nominations from more than 500 allied health employees, the awards highlighted the…
Enabling circular economy practices in sustainable metal production
Posted: 27 November 2024 Researchers in the DIAMETER project will develop digital platforms focused on augmented sustainability and circularity of additive manufacturing and machining processes. A new four-year project has been awarded €6 million (AUD$9.7 million) by the…
New hope for diabetic heart disease treatment
Posted: 27 November 2024 Monash University drug discovery researchers have found that a natural fat molecule called ‘lipoxin A4’ (LXA4) could significantly reduce inflammation and improve function for diabetic hearts. The preclinical study, published in Cardiovascular Diabetology, found LXA4, which…
Monash-led research is expanding treatment options for high cholesterol
Posted: 27 November 2024 Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions. Monash University and Monash Health are…
$29.9 million in Linkage Projects to support research partnerships
Posted: 27 November 2024 The Australian Research Council (ARC) today announced $29.9 million in funding for 56 new projects under the ARC’s Linkage Project scheme 2024 Round 1. ARC Acting Chief Executive Officer, Dr Richard Johnson, said the…
Medicines Australia welcomes announcement of HTA Implementation Advisory Group and two industry representatives
Posted: 27 November 2024 Medicines Australia welcomes the announcement of the independent HTA Reform Implementation Advisory Group and the appointment of CEO Liz de Somer and Board Deputy Chair Anne Harris as industry’s representatives. “The independent Implementation Advisory…
SUCCESSFUL COMPLETION OF PLANNED IDMC REVIEW OF ACTION3 PHASE 3 FSGS KIDNEY TRIAL
Posted: 20 November 2024 Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, today confirmed that the Independent Data Monitoring Committee (IDMC) successfully concluded a fifth review of the ACTION3 phase 3 clinical…
ViiV HEALTHCARE ANNOUNCES DATA DEMONSTRATING DOVATO (DTG/3TC) IS HIGHLY EFFECTIVE IN TREATMENT-NAIVE PEOPLE WITH ADVANCED HIV
Posted: 20 November 2024 ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación Huésped and the Bahiana Foundation of…
